Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?
The Motley Fool
by newsfeedback@fool.com (Prosper Junior Bakiny)February 20, 2026
AI-Generated Deep Dive Summary
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?
CRISPR Therapeutics (NASDAQ: CRSP) has made significant strides in the biotech industry, particularly with its groundbreaking gene-editing therapies. The company developed Casgevy, a treatment for rare blood diseases that became the first gene-editing therapy approved using the Nobel Prize-winning CRISPR system. Despite this success, the stock has underperformed since the breakthrough, leaving investors wondering if it will reach new heights or
Verticals
financeinvesting
Originally published on The Motley Fool on 2/20/2026